Johnson & Johnson vs PTC Therapeutics: Which Stock Could Rally?
Johnson & Johnson surged 16% during the past Month. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer PTC Therapeutics gives you more. PTC Therapeutics (PTCT) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Johnson & Johnson (JNJ) stock, suggesting you may be better off investing in PTCT
- PTCT’s quarterly revenue growth was 7.2%, vs. JNJ’s 6.8%.
- In addition, its Last 12 Months revenue growth came in at 97.5%, ahead of JNJ’s 5.1%.
- PTCT’s LTM margin is higher: 51.8% vs. JNJ’s 26.2%.
These differences become even clearer when you look at the financials side by side. The table highlights how JNJ’s fundamentals stack up against those of PTCT on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| JNJ | PTCT | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 23.7 | 6.2 | PTCT |
| Revenue Growth | |||
| Last Quarter | 6.8% | 7.2% | PTCT |
| Last 12 Months | 5.1% | 97.5% | PTCT |
| Last 3 Year Average | 6.1% | 41.7% | PTCT |
| Operating Margins | |||
| Last 12 Months | 26.2% | 51.8% | PTCT |
| Last 3 Year Average | 26.4% | -8.9% | JNJ |
| Momentum | |||
| Last 3 Year Return | 58.3% | 50.6% | JNJ |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: JNJ Revenue Comparison | PTCT Revenue Comparison
See more margin details: JNJ Operating Income Comparison | PTCT Operating Income Comparison
See detailed fundamentals on Buy or Sell PTCT Stock and Buy or Sell JNJ Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| JNJ Return | 11% | 6% | -9% | -5% | 47% | 13% | 72% | ||
| PTCT Return | -35% | -4% | -28% | 64% | 68% | -3% | 21% | ||
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 83% | <=== | |
| Monthly Win Rates [3] | |||||||||
| JNJ Win Rate | 58% | 58% | 50% | 42% | 83% | 100% | 65% | <=== | |
| PTCT Win Rate | 33% | 58% | 42% | 83% | 58% | 0% | 46% | ||
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | 62% | ||
| Max Drawdowns [4] | |||||||||
| JNJ Max Drawdown | -2% | -7% | -16% | -7% | -2% | -1% | -6% | <=== | |
| PTCT Max Drawdown | -42% | -36% | -53% | -12% | -20% | -5% | -28% | ||
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | -7% | ||
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 2/5/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read PTCT Dip Buyer Analyses to see how the stock has fallen and recovered in the past.
Still not sure about JNJ or PTCT? Consider portfolio approach.
Move Beyond Single Stocks With A Multi Asset Portfolio
Stocks soar and sink but bonds commodities and other assets balance the ride. A multi asset portfolio keeps returns steadier and reduces single market risk.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices